GlassScriptPhysician profile
Adrian M Escontrias
NPI 1316044050
$1,548.18
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $190 · 2021: $113 · 2022: $83.11 · 2023: $155 · 2024: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $396.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.23 | 2019-2024 | Relistor |
| Abbvie INC. | $203.23 | 2021-2024 | |
| Nevro Corp. | $103.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $90.83 | 2019 | |
| Collegium Pharmaceutical, INC. | $88.48 | 2019-2023 | Xtampza |
| Mdd US Operations, LLC | $87.92 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $79.55 | 2024 | |
| Allergan, INC. | $40.51 | 2020 | |
| Pfizer INC. | $38.28 | 2019-2020 | |
| Boston Scientific Corporation | $32.05 | 2019 | |
| Upsher-Smith Laboratories LLC | $31.50 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $30.98 | 2021 | |
| Lilly USA, LLC | $21.37 | 2020 | |
| Daiichi Sankyo INC. | $19.18 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $18.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.53 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.28 | 2019 | |
| Fidia Pharma USA INC. | $14.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Escontrias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.